Urology
News, opinions and meeting coverage in urology.
FDA Warns of High-Grade Prostate Ca Risk With BPH Drugs
WASHINGTON -- The FDA has issued a warning of an increased risk of high-grade prostate cancer with the 5-alpha reductase inhibitors finasteride (Proscar) and dutasteride (Avodart), currently approved to treat benign prostatic hypertrophy.
Jun 09, 2011